ADDITION THERAPEUTICS

Matilde Bertolini, PhD

Turning hepatocytes into incretin factories with PRINT™, an RNA-based genetic medicine platform

ASGCT Annual Meeting 2026 - Boston, MA - Presented by Addition Therapeutics

PRINT: Combining the best of RNA therapeutics and viral gene therapies



ADDITION THERAPEUTICS

Core of our platform is an all-RNA system using an R2 retrotransposase

Precise RNA-mediated INsertion of Transgenes



Universal Retrotransposase mRNA
Conventional mRNA

"Plug and Play" Template RNA
Proprietary sequences, Cargo agnostic

Lipid Nanoparticle
Low immunogenicity, repeat dose

Target:

Ribosomal safe harbor

~300-700 copies in human genome



Result:

Protein expression

Endogenous to human genome or Exogenous protein therapeutic

Abstract on PRINT platform (#103) was presented at ASGCT by Greg Cost on Tuesday, May 12th

ADDITION THERAPEUTICS

PRINT is well-suited to address the challenges of severe, medically-driven obesity

Severe, morbid obesity is a lifelong medical condition that cannot be managed through lifestyle changes alone.
Reduces life expectancy by 5-15 years

Current therapies:

Treatment burden:
Daily or weekly administrations

Side effects burden:
Cardiac, hyper-pigmentation, nausea, …

Long term outcome:
Contingent on compliance

PRINT potential:

- **Multi-year durability** eliminates dosing burden
- **Flat PK** improves efficacy and tolerance
- **Redosability and tunability** control therapeutic exposure



ADDITION THERAPEUTICS

PRINTed incretin mimetics show high potency profile





ADDITION THERAPEUTICS

Sustained expression of an incretin mimetic correlates with reduced weight gain in a DIO model

GLP1RA-02 (first generation template)

GLP1RA-02 serum levels (up to 19 weeks post-PRINT)



GLP1RA-02 effect on weight gain



ADDITION THERAPEUTICS

Engineering of templates achieves enhanced PRINT of incretin mimetics in cell lines



GLP1RA-01 template optimizations



ADDITION THERAPEUTICS

Efficient PRINT of incretin mimetics results in reduced weight gain in mice on standard diet

GLP1RA-01

Serum levels (6 weeks post-PRINT)



Weight gain suppression



Non-fasting biomarker levels



ADDITION THERAPEUTICS

Efficient PRINT of incretin mimetics results in reduced weight gain in mice on standard diet

GLP1RA-02

Serum levels (3 weeks post-PRINT)



Weight gain suppression



ADDITION THERAPEUTICS

Switch allows for dose-dependent, permanent PRINT turn-off with an FDA-approved molecule

Dimmer switch for tunable reversibility

Failsafe switch for complete termination

Inducible apoptosis switch

- Clinical validation and long development history
- Low immunogenicity and genotoxicity
- Short time for activation

***In vitro* proof-of-concept of PRINT safety switch with fluorescent reporter**



ADDITION THERAPEUTICS

PRINT: a path to a durable, tunable therapy for severe, chronic obesity

PRINT

PRINT combines the **tolerability and redosability of RNA therapeutics** with the **durability of gene therapy,** enabling sustained transgene expression from a single, repeatable dose.

Template engineering campaigns successfully **raise expression of incretin mimetics with strong potency profiles.**

PRINTed incretin mimetics result in up to **21% lower weight gain** in mice on standard diet and **exposure correlates with weight gain suppression in a DIO model**.

A built-in, clinically validated safety switch enables both **fine-tuning and full reversal** of therapy.

ADDITION THERAPEUTICS

Acknowledgements – it takes a village!

ADDITION THERAPEUTICS



Therapeutic Technologies



LNP Formulation



Operations



Pharmaceutical Sciences



Pre-clinical Translation

Thank you

ADDITION THERAPEUTICS